Paraneoplastic neurological disorders

References

• Dalmau J, Graus F. Paraneoplastic syndromes of the nervous system. In: Cancer of the Nervous System. Loeffler JS (Ed.). Blackwell Scietific Publications, Oxford, UK, 674–700 (1997).
   Google Scholar
• Heidenreich F, Schober R, Brinck U, Hartung HP. Multiple paraneoplastic syndromes in a patient with antibodies to neuronal nucleoproteins (anti-Hu). J. Neurol.242(4), 210–216 (1995).
   PubMed Web of Science ®Google Scholar
• O´Neill JH, Murray NM, Newsom-Davis J. The Lambert–Eaton myasthenic syndrome. A review of 50 cases. Brain111(Pt 3), 577–596 (1988).
   PubMedGoogle Scholar
• Graus F, DelattreJY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol Neurosurg. Psychiatry75(8), 1135–1140 (2004).
   PubMed Web of Science ®Google Scholar
• Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr. Opin. Pharmacol.9(3), 336–340 (2009).
   PubMed Web of Science ®Google Scholar
• Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert–Eaton myasthenic syndrome. J. Neurol. Sci.147(1), 35–42 (1997).
   PubMed Web of Science ®Google Scholar
• Isaacs H. A syndrome of continuous muscle-fibre activity. J. Neurol. Neurosurg. Psychiatry24, 319–325 (1961).
   PubMed Web of Science ®Google Scholar
• Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune etiology for acquired neuromyotonia. Lancet338, 75–77 (1991).
   PubMed Web of Science ®Google Scholar
• Partanen VSJ, Soininen H, Saksa M, Riekkinen P. Electromyographic and nerve conduction findings in a patient with neuromyotonia, normcalcemic tetany and small cell lung cancer. Acta Neurol. Scand.61, 216–226 (1980).
   PubMedGoogle Scholar
• Evoli A, Lo Monaco M, Marra R, Lino MM, Batocchi AP, Tonali PA. Multiple paraneoplastic diseases associated with thymoma. Neuromuscul. Disord.9(8), 601–603 (1999).
   PubMed Web of Science ®Google Scholar
• Lahrmann H, Albrecht G, Drlicek M et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin´s disease. Muscle Nerve24(6), 834–838 (2001).
   PubMed Web of Science ®Google Scholar
• Voltz RD, Albrich WC, Nagele A et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology49(5), 1454–1457 (1997).
   PubMed Web of Science ®Google Scholar
• Yamamoto AM, Gajdos P, Eymard B et al. Anti-titin antibodies in myasthenia gravis. Arch. Neurol.58(6), 885–890 (2001).
   PubMed Web of Science ®Google Scholar
• Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology57(9), 1579–1582 (2001).
   PubMed Web of Science ®Google Scholar
• Vural B, Chen LC, Saip P et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer103(12), 2575–2583 (2005).
   PubMed Web of Science ®Google Scholar
• Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndrome. Neurology70(12), 924–928 (2008).
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Klooster R, Potman M et al. SOX antibodies in small cell lung cancer and Lambert–Eaton myasthenic syndrome: frequency and relation with survival. J. Clin. Oncol.27(26), 4260–4267 (2009).
   PubMed Web of Science ®Google Scholar
• Vincent A. Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol. Rev.60(3), 756–824 (1980).
   PubMed Web of Science ®Google Scholar
• Vincent A, Jacobson L, Plested P et al. Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita. Ann. NY Acad. Sci.841, 482–496 (1998).
   PubMed Web of Science ®Google Scholar
• Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma cell line. Nature317(6039), 737–739 (1985).
   PubMed Web of Science ®Google Scholar
• Lang B, Newsom-Davis J, Wray D, Murray N. Autoimmune etiology for myasthenic (Eaton–Lambert) syndrome. Lancet2(8240), 224 (1981).
   PubMed Web of Science ®Google Scholar
• Venuta F, Rendina EA, De Giacomo T et al. Thymectomy for myasthenia gravis: a 27-year experience. Eur. J. Cardiothorac. Surg.15(5), 621–624 (1999).
   PubMed Web of Science ®Google Scholar
• Toyka KV. Myasthenia gravis. In: Current Therapy in Neurologic Diseases III. Johnson RT (Ed.). BC Decker, PA, USA, 385–391 (1990).
   Google Scholar
• Gajdos PH, Chevret S, Clair B, Tranchant C, Chastang C. Clinical-trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol.41(6), 789–796 (1997).
   PubMed Web of Science ®Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert–Eaton myasthenic syndrome. N. Engl. J. Med.321, 1567–1571 (1989).
   PubMed Web of Science ®Google Scholar
• Chalk CH, Murray NM, Newsom-Davis J et al. Response of the Lambert–Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology40(10), 1552–1556 (1990).
   PubMed Web of Science ®Google Scholar
• Sanders DB. Lambert–Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann. Neurol.37(Suppl. 1), S63–S73 (1995).
   PubMedGoogle Scholar
• Newsom-Davis J, Murray N, Wray D et al. Lambert–Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve5(9S), S17–S20 (1982).
   PubMedGoogle Scholar
• Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in Lambert–Eaton myasthenic syndrome. Neurology34(4), 480–485 (1984).
   PubMed Web of Science ®Google Scholar
• Bain PG, Motomura M, Newsom-Davis J et al. Effect of intravenous immunoglobulin (IvIg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology47(3), 678–683 (1996).
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Mills K. Immunological associations of acquired neuromyotonia (Isaacs´syndrome). Report of five cases and literature review. Brain116(Pt 2), 453–469 (1993).
   PubMedGoogle Scholar
• Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J. Neurol. Sci.181(1–2), 38–43 (2000).
   PubMed Web of Science ®Google Scholar
• Graus F, Delattre JY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry75(8), 1135–1140 (2004).
   PubMed Web of Science ®Google Scholar
• Camdessanché JP, Antoine JC, Honnorat J et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain125(Pt 1), 166–175 (2002).
   PubMed Web of Science ®Google Scholar
• Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N. Engl. J. Med.343(12), 847–855 (2000).
   PubMed Web of Science ®Google Scholar
• Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol.7(4), 327–340 (2008).
   PubMed Web of Science ®Google Scholar
• Sabater L, Bataller L, Carpentier AF et al. Protein kinase C γ autoimmunity in paraneoplastic cerebellar degeneration and nonsmall-cell lung cancer. J. Neurol. Neurosurg. Psychiatry77, 1359–1362 (2006).
   PubMedGoogle Scholar
• Sillevis Smitt P, Kinoshita A, De Leeuw B et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl. J. Med.342(1), 21–27 (2000).
   PubMedGoogle Scholar
• Luque FA, Furneaux HM, Ferziger R et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann. Neurol.29(3), 241–251 (1991).
   PubMed Web of Science ®Google Scholar
• Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus–myoclonus syndrome. Ann. Neurol.53(3), 347–353 (2003).
   PubMed Web of Science ®Google Scholar
• Didelot A, Honnorat J. Update on paraneoplastic neurological syndromes. Curr. Opin. Oncol.21(6), 566–572 (2009).
   PubMedGoogle Scholar
• Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol.7(12), 1091–1098 (2008).
   PubMed Web of Science ®Google Scholar
• Vincent A, Buckley C, Schott JM et al. Potassium channel antibody-asociated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain127(Pt 3), 701–712 (2004).
   PubMed Web of Science ®Google Scholar
• Ances BM, Vitaliani R, Taylor RA et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain128(Pt 8), 1764–1777 (2005).
   PubMed Web of Science ®Google Scholar
• Lai M, Hughes EG, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol.65(4), 424–434 (2009).
   PubMed Web of Science ®Google Scholar
• De Camilli P, Thomas A, Cofiell R et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-man syndrome with breast cancer. J. Exp. Med.178(6), 2219–2223 (1993).
   PubMed Web of Science ®Google Scholar
• Vernino S, Tuite P, Adler CH et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann. Neurol.51(5), 625–630 (2002).
   PubMed Web of Science ®Google Scholar
• Honnorat J, Cartalat-Carel S, Ricard D et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J. Neurol. Neurosurg. Psychiatry80(4), 412–416 (2009).
   PubMed Web of Science ®Google Scholar
• Cross SA, Salomao DR, Parisi JE et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann. Neurol.54(1), 38–50 (2003).
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J, Valldeoriola F et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin´s disease. J. Neuroimmunol.74(1–2), 55–61 (1997).
   PubMed Web of Science ®Google Scholar
• Vedeler CA, Antoine JC, Giometto B et al. Management of paraneoplastic neurological syndromes: report on an ENS task force. Eur. J. Neurol.13(7), 682–690 (2006).
   PubMed Web of Science ®Google Scholar
• Younes-Mhenni S, Janier MF, Cinotti L et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain127(10), 2331–2338 (2004).
   PubMed Web of Science ®Google Scholar
• Graus F, Vega F, Delattre JY et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology42(3 Pt 1), 536–540 (1992).
   PubMedGoogle Scholar
• Graus F, Keime-Guibert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain124(Pt 6), 1138–1148 (2001).
   PubMed Web of Science ®Google Scholar
• Blaes F, Strittmatter M, Merkelbach S et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J. Neurol.246(4), 299–303 (1999).
   PubMed Web of Science ®Google Scholar
• Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma-associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J. Neurol. Neurosurg. Psychiatry67, 7–14 (1999).
   PubMed Web of Science ®Google Scholar
• Tschernatsch M, Stolz E, Strittmatter M, Kaps M, Blaes F. Antinuclear antibodies define a subgroup of paraneoplastic neuropathies – clinical and immunological data. J. Neurol. Neurosurg. Psychiatry76(12), 1702–1706 (2005).
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain127(Pt 8), 1831–1844 (2004).
   PubMed Web of Science ®Google Scholar
• Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol.15(9), 893–908 (2008).
   PubMed Web of Science ®Google Scholar
• Wilkinson PC. Serologic findings in carcinomatous neuromyopathy. Lancet1, 1301–1303 (1964).
   PubMed Web of Science ®Google Scholar
• Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am. J. Pathol.141(4), 881–886 (1992).
   PubMed Web of Science ®Google Scholar
• Anderson NE, Budde-Steffen C, Rosenblum MK et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine67(2), 100–109 (1988).
   PubMed Web of Science ®Google Scholar
• Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein NOVA-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc. Natl. Acad. Sci. USA95(22), 13254–13259 (1998).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann. Neurol.53(5), 580–587 (2003).
   PubMed Web of Science ®Google Scholar
• Dalmau J, Gultekin SH, Voltz R et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain122, 27–39 (1999).
   PubMed Web of Science ®Google Scholar
• Voltz R, Gultekin SH, Rosenfeld M et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N. Engl. J. Med.340, 1788–1795 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann. Neurol.50, 339–348 (2001).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann. Neurol.18(5), 592–600 (1985).
   PubMed Web of Science ®Google Scholar
• Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry61(3), 270–278 (1996).
   PubMed Web of Science ®Google Scholar
• Antoine JC, Honnorat J, Camdessanche JP et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann. Neurol.49(2), 214–221 (2001).
   PubMed Web of Science ®Google Scholar
• Honnorat J, Byk T, Kusters I et al. Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur. J. Neurosci.11(12), 4226–4232 (1999).
   PubMed Web of Science ®Google Scholar
• Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G; PND Euronetwork. Paraneoplastic neurologic syndrome in the PND Euronetwork database: a European study from 20 centers. Arch. Neurol.67(3), 330–335 (2010).
   PubMedGoogle Scholar
• Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann. Neurol.47, 297–305 (2000).
   PubMed Web of Science ®Google Scholar
• Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann. Neurol.50, 301–311 (2001).
   PubMed Web of Science ®Google Scholar
• Tschernatsch M, Klotz M, Probst C et al. Synaptophysin is an autoantigen in paraneoplastic neuropathy. J. Neuroimmunol.197(1), 81–86 (2008).
   PubMedGoogle Scholar
• Dropcho EJ. Antiamphiphysin antibodies with small cell lung carcinoma and paraneoplastic encephalomyelitis. Ann. Neurol.39(5), 659–667 (1996).
   PubMed Web of Science ®Google Scholar
• Sommer C, Weishaupt A, Brinkhoff J et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet365(9468), 1406–1411 (2005).
   PubMed Web of Science ®Google Scholar
• Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun. Rev.8(5), 410–414 (2009).
   PubMed Web of Science ®Google Scholar
• Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest. Ophthalmol. Vis. Sci.38(2), 283–291 (1997).
   PubMed Web of Science ®Google Scholar
• Kimpinski K, Iodice V, Vernino S, Sandroni P, Low PA. Association of N-type calcium channel autoimmunity in patients with autoimmune autonomic ganlgionopathy. Auton. Neurosci.150(1–2), 136–139 (2009).
   PubMed Web of Science ®Google Scholar
• Buckley C, Oger J, Clover L et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann. Neurol.50(1), 73–78 (2001).
   PubMed Web of Science ®Google Scholar
• Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology70(20), 1883–1890 (2008).
   PubMed Web of Science ®Google Scholar
• Irani SR, Bera K, Waters P et al.N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain13(Pt 6), 1655–1667 (2010).
   Google Scholar
• Lancaster E, Lai M, Peng X et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol.9(1), 67–76 (2010).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med.202(4), 473–477 (2005).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA. Aquaporin-4 antibodies in a paraneoplastic context. Arch. Neurol.65(5), 629–632 (2008).
   PubMed Web of Science ®Google Scholar
• Verschuuren JJ, Dalmau J, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: studies on human tumor cell lines. J. Neuroimmunol.79(2), 202–210 (1997).
   PubMedGoogle Scholar
• Schäfer KH, Klotz M, Mergner D, Mestres P, Schimrigk K, Blaes F. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J. Autoimmun.15(4), 479–484 (2000).
   PubMed Web of Science ®Google Scholar
• Greenlee JE, Parks, TN, Jaeckle KA. Type IIa (anti-Hu) antineuronal antibodies produce destruction of rat cerebellar granule neurones in vitro. Neurology43(10), 2049–2054 (1993).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Tanaka K, Onodera O, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. Clin. Neurol. Neurosurg.97(1), 95–100 (1995).
   PubMed Web of Science ®Google Scholar
• Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med.4(11), 1321–1324 (1998).
   PubMed Web of Science ®Google Scholar
• Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology51(4), 1146–1150 (1998).
   PubMed Web of Science ®Google Scholar
• Roberts WK, Deluca IJ, Thomas A et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J. Clin. Invest.119(7), 2042–2051 (2009).
   PubMedGoogle Scholar
• Pellkofer H, Schubart AS, Höftberger R et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain127(Pt 8), 1822–1830 (2004).
   PubMedGoogle Scholar
• Kazarian M, Calbo J, Proost N, Carpenter CL, Berns A, Laird-Offringa IA. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J. Neuroimmunol.217(1–2), 38–45 (2009).
   PubMedGoogle Scholar
• Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer – a quantitative Western Blot analysis. Ann. Neurol.27(5), 544–552 (1990).
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J, Rene R et al. Anti-Hu antibodies in patients with small cell lung cancer: association with complete response to therapy and improved survival. J. Clin. Oncol.15(8), 2866–2872 (1997).
   PubMed Web of Science ®Google Scholar
• Blaes F, Klotz M, Huwer H et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann. Thorac. Surg.69(1), 254–258 (2000).
   PubMed Web of Science ®Google Scholar
• Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso–myoclonus and neuroblastoma. Cancer37(6), 846–852 (1976).
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Cheung NK et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer75(1), 99–109 (1995).
   PubMed Web of Science ®Google Scholar
• Cohn SL, Salwen H, Herst CV et al. Single copies of the n-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus–myoclonus. Cancer62(5), 723–726 (1988).
   PubMed Web of Science ®Google Scholar
• Hahn A, Claviez A, Brinkmann G, Altermatt HJ, Schneppenheim R, Stephani U. Paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Neuropediatrics31(1), 42–44 (2000).
   PubMed Web of Science ®Google Scholar
• Blaes F, Lang B. Opsoclonus–myoclonus syndrome in childhood. In: Autoantibodies in Neurological Diseases. Vincent A, Martino G (Eds). Springer, Milan, Italy, 144–151 (2001).
   Google Scholar
• Korfei M, Fühlhuber V, Schmidt-Wöll T et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus–myoclonus syndrome. J. Neuroimmunol.170(1–2), 150–157 (2005).
   PubMed Web of Science ®Google Scholar
• Blaes F, Fühlhuber V, Korfei M et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann. Neurol.58(2), 313–317 (2005).
   PubMed Web of Science ®Google Scholar
• Sabater L, Xifro X, Saiz A, Alberch J, Graus F. Analysis of autoantibodies to neuronal surface antigens in adult opsoclonus myoclonus. J. Neuroimmunol.196(1–2), 188–191 (2008).
   PubMed Web of Science ®Google Scholar
• Fühlhuber V, Bick S, Kirsten A et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus–myoclonus syndrome. J. Neuroimmunol.210(1–2), 87–91 (2009).
   PubMed Web of Science ®Google Scholar
• Pranzatelli MR, Tate ED, Travelstead AL et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J. Pediatr. Hematol. Oncol.28(9), 585–593 (2006).
   PubMed Web of Science ®Google Scholar
• Russo C, Cohn SL, Petruzzi MJ, Alarcon PA. Long-term neurologic outcome in children with opsoclonus–myoclonus associated with neuroblastoma: a report from the pediatric oncology group. Med. Pediatr. Oncol.28(4), 284–288 (1997).
   PubMed Web of Science ®Google Scholar
• Vernino S. Neuronal acetylcholine receptor autoimmunity. Ann. NY Acad. Sci.1132, 124–128 (2008).
   PubMedGoogle Scholar
• McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody. Arch. Neurol.66(6), 735–741 (2009).
   PubMedGoogle Scholar